Par Drugs And Chemicals Limited · NSE:PAR
Par Drugs And Chemicals — H1 FY2023 Earnings Presentation
16 slides from Par Drugs And Chemicals's earnings presentation, Nov 12, 2022
Slide 1: Cover letter to National Stock Exchange
PAR/CS/NSE/2022-23/45 To, Date: 12/11/2022 The Manager Listing department, National Stock Exchange of India Limited Exchange Plaza, C-1, Block-G, Bandra Kurla Complex, Bandra (E), Mumbai- 400 051 Maharashtra Symbol - PAR, ISIN: INE04LG01015 Subject: Investors Presentation Ref.: Regulation 30 read wi
Slide 2: Q2/H1-FY23 Earnings Presentation
Q2/H1-FY23 Earnings Presentation
Slide 3: Company Overview
Company Overview
Slide 4: Company Overview
3 Company Overview Operational Revenues (INR Mn) • Promoted by Mr. Falgun Savani and Mr. Jignesh Savani, Par Drugs and Chemicals Limited (PDCL) was founded in 1982 and is engaged in the development 209 and manufacturing of APIs. 194 218 • The Company today manufactures 25 different products and all
Slide 5: Key Strengths
4 Key Strengths Diversified Portfolio: The company manufactures the entire range of products in the Antacid segment. The product portfolio presently comprises 15 APIs and 10 Fine Chemicals which are marketed domestically and exported. Global Presence: The Company is operating both in domestic and ex
Slide 6: Financial & Operational Highlights
FINANCIAL & OPERATIONAL HIGHLIGHTS
Slide 7: Q2/H1-FY23 Financial & Operational Highlights
6 Q2/H1-FY23 Financial & Operational Highlights Q2-FY23 Financial Highlights Operational Highlights • Sales growth in the domestic market was 42% whereas on the export market front it was at around 11%. Revenue EBITDA EBITDA Margin INR 248 Mn INR 59 Mn 23.79% • There has been an increase in sales of
Slide 8: Q2/H1-FY23 Financial Overview
Q2/H1-FY23 Financial Overview
Slide 9: Quarterly Income Statement (IND-AS)
8 Quarterly Income Statement (IND-AS) Income Statement (INR Mn) Q2-FY23 Q2-FY22 Y-o-Y Q1-FY23 Q-o-Q Income from Operations 248 196 26.5% 235 5.5% Total Expenses 189 156 21.2% 198 (4.5)% EBITDA 59 40 47.5% 37 59.5% EBITDA Margins (%) 23.79% 20.41% 338 Bps 15.74% 805 Bps Finance Cost 0 2 NA 1 NA Depre
Slide 10: Half-Yearly Income Statement (IND-AS)
9 Half-Yearly Income Statement (IND-AS) Income Statement (INR Mn) H1-FY23 H1-FY22 Y-o-Y Income from Operations 483 361 33.8% Total Expenses 388 280 38.6% EBITDA 95 81 17.3% EBITDA Margins(%) 19.66% 22.44% (278) Bps Finance Cost 1 3 (66.7)% Depreciation 16 16 NA Other Income 2 1 NA Profit Before Tax
Slide 11: Historical Income Statement
10 Historical Income Statement Income Statement (INR Mn) FY20 FY21 FY22 H1-FY23 Income from Operations 558 608 751 483 Total Expenses 464 447 588 388 EBITDA 94 161 163 95 EBITDA Margins (%) 16.85% 26.48% 21.70% 19.66% Finance Cost 8 7 5 1 Depreciation 27 28 33 16 Other Income 1 2 2 2 Profit before E
Slide 12: Balance Sheet
11 Balance Sheet EQUITIES & LIABILITIES (INR Mn) FY21 FY22 H1-FY23 ASSETS (INR Mn) FY21 FY22 H1-FY23 Shareholder Funds 522 599 659 Non Current Assets 352 351 363 (A) Equity Share Capital 61 123 123 (A) Fixed Assets - - - (B) Reserves & Surplus 461 476 536 (i) Tangible Assets 299 341 331 (ii) Capital
Slide 13: Financial Highlights
12 Financial Highlights Operational Revenue (INR Mn) EBITDA (INR Mn) & EBITDA Margins (%) PAT (INR Mn) & PAT Margins (%) 751 26.48% 21.70% 19.08% 608 558 19.66% 483 16.85% 12.25% 12.42% 8.60% 116 60 92 94 161 163 95 48 FY20 FY21 FY22 H1-FY23 FY20 FY21 FY22 H1-FY23 FY20 FY21 FY22 H1-FY23 RoCE & RoE N
Slide 14: Capital Market Highlights
13 Capital Market Highlights Stock Market Performance (as on 30th September, 2022) 40% 20% 0% -20% -40% -60% 01-Oct 01-Nov 01-Dec 01-Jan 01-Feb 01-Mar 01-Apr 01-May 01-Jun 01-Jul 01-Aug 01-Sep Par Drugs Nifty 50 52 Price Data (30th September, 2022) INR Shareholding Pattern as on 30th September, 2022
Slide 15: Disclaimer
14 Disclaimer Par Drugs and Chemicals Limited: The above Presentation with slides have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection w
Slide 16: Thank You
Thank You
Par Drugs and Chemicals — H1 FY2023 Earnings Presentation on 6ix